BSX - Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today? | Benzinga
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value of approximately $3.7 billion.
The Axonics product portfolio includes the Axonics R20TM and the Axonics F15TM Systems used to deliver sacral neuromodulation (SNM) therapy.
SNM therapy is a minimally invasive procedure used in the treatment of OAB and ...